MX2024011043A - Combinaciones terapéuticas, composiciones y métodos para diseñar y producir estados mentales entactogénos - Google Patents
Combinaciones terapéuticas, composiciones y métodos para diseñar y producir estados mentales entactogénosInfo
- Publication number
- MX2024011043A MX2024011043A MX2024011043A MX2024011043A MX2024011043A MX 2024011043 A MX2024011043 A MX 2024011043A MX 2024011043 A MX2024011043 A MX 2024011043A MX 2024011043 A MX2024011043 A MX 2024011043A MX 2024011043 A MX2024011043 A MX 2024011043A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- designing
- methods
- mental
- therapeutic combinations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263318369P | 2022-03-09 | 2022-03-09 | |
| PCT/US2023/014926 WO2023172701A2 (en) | 2022-03-09 | 2023-03-09 | Therapeutic combinations, compositions, and methods for designing and producing entactogenic mindstates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024011043A true MX2024011043A (es) | 2024-12-06 |
Family
ID=87935763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024011043A MX2024011043A (es) | 2022-03-09 | 2024-09-09 | Combinaciones terapéuticas, composiciones y métodos para diseñar y producir estados mentales entactogénos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250177354A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4489649A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025509432A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250011101A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119497589A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023232712A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3245622A1 (cg-RX-API-DMAC7.html) |
| CR (1) | CR20240417A (cg-RX-API-DMAC7.html) |
| IL (1) | IL315512A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024011043A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023172701A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250145285A (ko) * | 2024-03-28 | 2025-10-13 | 건국대학교 글로컬산학협력단 | 릴메니딘을 포함하는 정서장애의 예방, 개선 또는 치료용 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9721978D0 (en) * | 1997-10-17 | 1997-12-17 | Lilly Co Eli | Treatment of depression |
| DE19938823A1 (de) * | 1999-08-19 | 2001-02-22 | Boehringer Ingelheim Pharma | Medikamentöse Behandlung des Restless Leg Syndroms |
| CN101318020B (zh) * | 2007-06-06 | 2011-09-28 | 四川科瑞德制药有限公司 | 抗焦虑或/和抗抑郁的药物组合物及用途 |
| WO2014004676A1 (en) * | 2012-06-26 | 2014-01-03 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors as neuroprotective agents in the cns |
| US12414936B2 (en) * | 2017-02-09 | 2025-09-16 | Caamtech, Inc. | Compositions comprising a serotonergic tryptamine compound |
-
2023
- 2023-03-09 JP JP2024553843A patent/JP2025509432A/ja active Pending
- 2023-03-09 CN CN202380038385.8A patent/CN119497589A/zh active Pending
- 2023-03-09 US US18/845,088 patent/US20250177354A1/en active Pending
- 2023-03-09 CA CA3245622A patent/CA3245622A1/en active Pending
- 2023-03-09 EP EP23767488.2A patent/EP4489649A4/en active Pending
- 2023-03-09 WO PCT/US2023/014926 patent/WO2023172701A2/en not_active Ceased
- 2023-03-09 KR KR1020247033694A patent/KR20250011101A/ko active Pending
- 2023-03-09 IL IL315512A patent/IL315512A/en unknown
- 2023-03-09 CR CR20240417A patent/CR20240417A/es unknown
- 2023-03-09 AU AU2023232712A patent/AU2023232712A1/en active Pending
-
2024
- 2024-09-09 MX MX2024011043A patent/MX2024011043A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20240417A (es) | 2025-03-04 |
| WO2023172701A3 (en) | 2023-11-09 |
| JP2025509432A (ja) | 2025-04-11 |
| US20250177354A1 (en) | 2025-06-05 |
| EP4489649A2 (en) | 2025-01-15 |
| IL315512A (en) | 2024-11-01 |
| WO2023172701A2 (en) | 2023-09-14 |
| EP4489649A4 (en) | 2026-07-01 |
| KR20250011101A (ko) | 2025-01-21 |
| CN119497589A (zh) | 2025-02-21 |
| AU2023232712A1 (en) | 2024-10-17 |
| CA3245622A1 (en) | 2023-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024013963A (es) | Un antagonista de il-4r util para el tratamiento o la prevencion del asma | |
| CO2021005146A2 (es) | Inhibidores selectivos de rgmc y el uso de los mismos | |
| MX2024004921A (es) | Derivados de piperidinilindol, metodos de preparacion y usos medicinales de estos. | |
| CL2019000268A1 (es) | Composición de cannabis. | |
| CR20200334A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| PY2036977A (es) | Derivados de cannabinoides como compuestos farmacéuticamente activos y métodos de preparación de los mismos | |
| MX2021003110A (es) | Agonistas del receptor x farnesoide y usos de los mismos. | |
| CL2020002774A1 (es) | Tratamiento combinado de fibrosis y/o angiogénesis ocular | |
| CR8718A (es) | Compuesto de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central | |
| MX2019011606A (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue. | |
| GT201400222A (es) | Agentes para tratar trastornos que implican la modulación de receptores de rianodina | |
| ECSP067021A (es) | Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar) | |
| MX2024013040A (es) | Pirfenidona enriquecida con deuterio y metodos para su uso | |
| MX2019013878A (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue. | |
| UY30829A1 (es) | Compuestos agonistas y antagonistas del receptor de esfinfosina-1-fosfato | |
| MX2019013893A (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue. | |
| CO2018008421A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP21030482A (es) | Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos | |
| PA8680701A1 (es) | Derivados de oxindol | |
| CL2023000371A1 (es) | Composiciones y métodos para inhibir la expresión de plp1. | |
| DOP2023000223A (es) | Composiciones y métodos para inhibir cetohexoquinasa (khk) | |
| CR10062A (es) | Composiciones y metodos de tratamiento para trastornos del sistema nervioso central | |
| CO2020001012A2 (es) | Compuestos bifuncionales | |
| ECSP067019A (es) | Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar) | |
| UY29735A1 (es) | Piperazinas sustituidas como antagonistas de receptores de glutamato metabotrópicos |